The Wolverine Stack: BPC-157 + TB-500 Healing Protocol (2026 Guide)
Most people running BPC-157 are not getting the full result. Not because the compound doesn't work (it does) but because they're treating a systemic problem with a localised tool and expecting it to be enough.
BPC-157 is a powerful acute repair signal. TB-500 is the systemic cellular machinery that sustains and scales that repair. Running one without the other means one mechanism is always the bottleneck. The Wolverine Stack addresses both simultaneously, which is why it is the protocol that most serious recovery researchers eventually converge on.
Why These Two Compounds
Understanding why this combination works requires understanding what each compound does in isolation, and specifically where each one runs into its limitations.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Its core action is localised angiogenesis, it drives the formation of new blood vessels at the injury site, improving oxygen and nutrient delivery, and it upregulates growth factors including VEGF and EGF that directly stimulate tissue repair (Sikiric et al., Curr Med Chem, 2023). It is fast-acting relative to most recovery compounds, and its effects on gut healing, nerve repair, and musculoskeletal tissue are well-documented in animal research.
What BPC-157 does not do as effectively is address the systemic cellular environment. It is a local signal, not a system-wide remodeller. If the cells responsible for repair (fibroblasts, satellite cells, endothelial cells) cannot migrate efficiently to the injury site, the local repair signal operates in a depleted workforce. That is where TB-500 becomes essential.
TB-500 is a synthetic analog of the actin-binding region of Thymosin Beta-4. Its primary mechanism is promoting actin polymerisation (Safer D et al., Proc Natl Acad Sci USA, 1990), which enables cell motility, the capacity of repair cells to move to where they are needed. TB-500 also has documented anti-inflammatory activity, reducing the chronic inflammatory signalling that blocks repair in long-standing injuries. And it promotes angiogenesis via VEGF upregulation (Smart N et al., Nature, 2007), which overlaps with BPC-157 and compounds the effect rather than duplicating it.
The combination works because BPC-157 is telling the body to repair a specific site aggressively while TB-500 is ensuring the cells capable of executing that repair are present, mobile, and operating in a non-inflammatory environment. Two different pathways, one outcome.
This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice.
Mechanism Comparison
| Property | BPC-157 | TB-500 |
|---|---|---|
| Primary mechanism | Angiogenesis, growth factor upregulation | Actin polymerisation, cell motility |
| Action scope | Localised / targeted | Systemic |
| Anti-inflammatory | Moderate | Strong |
| Onset of effects | Fast (days to 1–2 weeks) | Gradual (weeks 2–4) |
| Best tissue applications | Tendon, muscle, gut, nerve | Tendon, connective tissue, cardiac |
| Administration | Subcutaneous or oral (gut only) | Subcutaneous |
| Typical dose | 250–500mcg/day | 2–2.5mg twice weekly |
The Wolverine Stack Protocol
The protocol has two phases: a loading phase where both compounds are run at full research doses to establish therapeutic concentrations, and a maintenance phase that sustains those effects at lower frequency.
Loading phase (weeks 1–6)
- BPC-157: 250–500mcg subcutaneously, once or twice daily. Split dosing (morning and evening) is preferred for complex or multi-site injuries. For a single injury focus, once daily in the morning is sufficient.
- TB-500: 2–2.5mg subcutaneously, twice weekly. Typical schedule: Monday and Thursday, or any consistent two-day split with approximately 72 hours between doses.
- Duration: 4–6 weeks. At the 4-week mark, assess progress before deciding whether to extend to 6 weeks.
Maintenance phase (weeks 7–14)
- BPC-157: 250mcg subcutaneously once daily, or reduce to 3–4 times per week if primary injury has resolved.
- TB-500: 2mg every 2 weeks.
- Duration: 4–8 additional weeks, depending on injury status and goals.
Injection logistics
Both compounds can be injected at the same subcutaneous site in the same session, drawn into the same syringe, without interaction concerns. This simplifies the protocol significantly for daily BPC-157 administration on TB-500 injection days.
Common injection sites: lower abdomen (2–3 inches from the navel), upper outer thigh, flank. Rotate sites across the protocol to prevent localised irritation.
For targeted musculoskeletal injuries (a specific tendon, a chronic muscle tear) some researchers inject BPC-157 near the injury site rather than a neutral location. TB-500 is systemically distributed regardless of injection location, so neutral-site injection is standard.
Reconstitution
Both compounds require reconstitution with bacteriostatic water before use. A practical approach: reconstitute each vial separately to a concentration that makes your intended dose a clean round number on an insulin syringe. For BPC-157 at 5mg per vial, 5mL BAC water gives 1000mcg/mL, a 500mcg dose is exactly 0.5mL (50 units). For TB-500 at 10mg per vial, 5mL BAC water gives 2000mcg/mL, a 2mg dose is exactly 1mL (100 units on a 1mL syringe). Keep reconstituted vials refrigerated and use within 30 days.
What to Expect Week by Week
The timeline is not linear. BPC-157 tends to produce earlier observable effects; TB-500's contribution becomes more apparent as systemic cellular repair capacity improves.
Weeks 1–2
Inflammation reduction is often the first noticeable change, less morning stiffness, reduced pain during movement, improved range of motion in affected joints. BPC-157 is the primary driver in this phase. TB-500 is building systemic concentrations during this period.
Weeks 3–4
Tissue regeneration begins to show. Injuries that have been structurally compromised start to feel more stable. Pain during functional movement decreases more substantially. Energy available for training typically increases as the chronic inflammatory load drops. This is where TB-500's contribution becomes tangible.
Weeks 5–6
Most researchers in the loading phase report being within functional range by this point, not necessarily at 100%, but cleared of the limitations that were the reason for the protocol. Chronic tendinopathies and long-standing multi-site injuries may still be in active recovery. Acute injuries that were the primary target are often resolved.
Risks and Appropriate Caution
The safety profiles of BPC-157 and TB-500 individually are covered in their respective complete guides. For the combined stack, the key considerations are additive rather than interactive, there are no documented adverse interactions between the two compounds.
Running two compounds simultaneously means two sets of theoretical risks and two sets of unknowns around long-term human use. Both compounds influence angiogenic pathways. The theoretical concern about accelerating undiagnosed malignancy that applies to each compound individually applies to the combination as well. This is not a known effect in healthy research populations, but it is the most substantive risk consideration to be aware of.
The other practical consideration is cost. The Wolverine Stack is not inexpensive when run properly. Factor the combined cost of both compounds across a 6-week loading phase before committing to the protocol, it is meaningfully higher than running either compound alone.
Always work with a qualified clinician before making changes to your health protocol, particularly when combining compounds that act on tissue repair and inflammatory pathways.
Who This Stack Is For
Not every injury warrants both compounds. The Wolverine Stack is best suited to specific situations.
Strong candidates
Chronic injuries that have not responded to standard recovery approaches (physio, time, NSAIDs) are the primary use case. The stack is particularly well-suited to connective tissue injuries: rotator cuff, Achilles tendinopathy, patellar tendon, hip flexor complex. These tissues receive poor blood supply at baseline, which is exactly the environment where TB-500's angiogenic and cell migration effects, combined with BPC-157's acute repair signalling, have the most mechanical rationale.
Multi-site injury patterns (the athlete who has accumulated damage across multiple joints and tendons over years of training) are another strong candidate for the systemic TB-500 component rather than targeting a single site with BPC-157 alone.
Not the right tool for
Acute soft tissue injuries that are healing normally do not require the full stack. A muscle strain in its first week, responding well to standard recovery, is a BPC-157 protocol at most, possibly nothing beyond foundational recovery support. Deploying the Wolverine Stack on an injury with a normal healing trajectory is unnecessary and expensive. Save the stack for where BPC-157 alone is not getting the job done.
Supporting the Stack
Peptides operate within biological systems. The stack works best when the foundational environment supports it.
Collagen synthesis requires raw materials: Vitamin C (1g daily) and glycine (10–15g daily) are the two most evidence-supported additions for tendon and ligament repair. They do not replace the stack, they provide the substrate that the cellular repair processes TB-500 and BPC-157 stimulate actually use to build tissue.
Sleep quality directly affects growth hormone output and tissue repair rates. If sleep is compromised, the stack's efficacy is compromised. Address sleep before or alongside the protocol, not as an afterthought.
Controlled mechanical loading of injured tissue during the protocol improves outcomes relative to complete immobilisation. Tendons remodel in response to appropriate stress, complete rest removes the signal that tells the tissue how to rebuild. Work with a physiotherapist to establish appropriate loading parameters for your specific injury.
The Bottom Line
The Wolverine Stack works because the two compounds address genuinely different bottlenecks in the same healing process. BPC-157 drives the repair signal; TB-500 ensures the cells that execute that repair can get to where they are needed and work in an environment that supports rather than blocks them.
Run it within researched parameters, with appropriate clinical oversight, on injuries that actually warrant it. That is the protocol worth following.
Frequently Asked Questions
Why is it called the Wolverine Stack?
The name references Wolverine from the X-Men — specifically his regenerative healing ability. It is a community name for the BPC-157 and TB-500 combination that emerged in biohacking and research forums, reflecting the stack's reputation for accelerating recovery beyond what either compound achieves alone. It has no official origin and is not used in clinical literature.
Can I mix BPC-157 and TB-500 in the same syringe?
Yes. There are no documented interaction concerns between the two compounds. On days when both are due — for example, a TB-500 injection day during daily BPC-157 administration — you can draw both into a single insulin syringe and inject at the same site. This simplifies the protocol without any known downsides. Reconstitute each compound separately in its own vial first, then draw the required volumes into one syringe for injection.
How long before the Wolverine Stack produces noticeable results?
BPC-157 typically produces the first observable changes within 1–2 weeks — reduced inflammation, improved range of motion, less pain during movement. TB-500's contribution becomes more apparent in weeks 3–4 as systemic cellular repair capacity improves. Most researchers report being within functional range by the end of a 6-week loading phase, though chronic long-standing injuries may require the full maintenance phase to resolve fully.
Is the Wolverine Stack useful for performance enhancement rather than injury repair?
Both compounds have performance-adjacent effects beyond acute injury repair. TB-500's anti-inflammatory activity reduces systemic inflammatory load, which improves recovery between training sessions. BPC-157 has documented effects on tendon and ligament integrity that may support injury prevention under high training loads. Some researchers use a maintenance-phase version of the stack — lower doses, less frequent — as a structural support protocol during periods of high training volume. This is an anecdotal application without the same evidence base as the therapeutic injury use.
Can the Wolverine Stack be run year-round?
Continuous year-round use is not well-evidenced and is not the recommended approach. The loading and maintenance phase structure exists in part to allow rest periods where the body is not being actively stimulated by angiogenic and repair compounds. Most protocols are capped at 12–16 total weeks (loading plus maintenance) before a complete break. Running back-to-back cycles without rest periods introduces unknowns around long-term receptor adaptation and the theoretical angiogenic risk considerations that apply to both compounds.
What does the full Wolverine Stack protocol look like week by week?
During the loading phase (weeks 1 to 6), BPC-157 runs at 250 to 500mcg daily via subcutaneous injection and TB-500 at 2 to 2.5mg twice per week. During the maintenance phase (weeks 7 to 12), BPC-157 continues daily and TB-500 drops to once per week or once every two weeks. On days when both compounds are due, they are drawn into a single insulin syringe and injected together. After 12 total weeks, a rest period equal to the cycle length follows before deciding whether a further cycle is needed. Most researchers achieve functional recovery of the target injury within the loading phase; the maintenance phase consolidates structural repair and reduces the likelihood of relapse.
Read Next
Disclaimer: This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.